Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06777316 · ClinicalTrials.gov registry record · Phase 1
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
A Phase 1 study of Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma (Icc), sponsored by Cogent Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 15
- Study locations
NCT06777316 is a Phase 1 study of Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma (Icc) that is actively recruiting participants, run by Cogent Biosciences. The registered enrollment target is 110 participants, below the 384-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (71% lower). The trial reports 15 study locations across 13 states.
The verdict
NCT06777316, a Phase 1 study of Cholangiocarcinoma and Intrahepatic Cholangiocarcinoma (Icc), is actively recruiting participants, sponsored by Cogent Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.
Conditions Studied
Interventions
- DRUG CGT4859
Study Locations (15)
Florida
- Mayo Clinic Jacksonville - Jacksonville
- Moffitt Cancer Center - Tampa
Ohio
- The Christ Hospital - Cincinnati
- Taussig Cancer Center - Cleveland Clinic - Cleveland
Arizona
- Mayo Clinic Scottsdale - Scottsdale
California
- Stanford Cancer Institute - Palo Alto
Illinois
- University of Chicago Medicine Comprehensive Cancer Center - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic Rochester - Rochester
Pennsylvania
- Fox Chase cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06777316
The ClinicalTrials.gov registry entry for NCT06777316 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 384-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (71% lower). The listed sponsor is Cogent Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which CGT4859 is the first listed.
NCT06777316 reports 15 study locations spanning 13 distinct geographic areas - top geographies include Florida, Ohio, Arizona.
Frequently Asked Questions
What is clinical trial NCT06777316 about?
NCT06777316 is a clinical study titled "A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors". This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid ...
What is the current status of trial NCT06777316?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2025-01-22. Estimated completion is 2027-06.
What conditions does trial NCT06777316 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma (Icc), Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification.
What interventions are being tested in trial NCT06777316?
The interventions under investigation include: CGT4859 (DRUG).
Who is sponsoring clinical trial NCT06777316?
This trial is sponsored by Cogent Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06777316 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
RECRUITING · Phase 1
-
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
-
A Study of MGC028 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.